期刊文献+

不稳定性心绞痛冠脉介入治疗前后NT-proBNP水平变化观察 被引量:1

下载PDF
导出
摘要 目的 通过观察不稳定型心绞痛(UAP)患者在冠脉介入治疗前和后氨基末端脑钠肽前体(NT-proBNP)水平变化来探讨心肌缺血与( NT-proBNP)的关系。方法 选择2011年4~9月于我院循环科住院的1~3天无心绞痛发作不稳定性心绞痛72例行冠状动脉造影检查,病变适宜的接受冠脉介入治疗。术前、术后16~24小时进行超声心动图检查和血浆( NT-proBNP )浓度测定,术后72~76小时复查血浆( NT-proBNP )水平。结果 单纯冠脉造影( CAG组)35例,冠状动脉介入治疗(PCI组)37例,CAG组术前和术后16~24小时的( NT-proBNP)水平及左室射血分数( LVEF)无明显变化( P>0.05);PC1组术后16~24小时的血浆(NT-proBNP)浓度高于术前(P<0.05),LVEF无统计学意义(P>0.05);术后72~76小时血浆(NT-proBNP)浓度与术前基本相当(P<0.05)。结论 在心功能正常(LVEF)正常的情况下,(UAP)患者介入治疗后血浆( NT-proBNP)浓度暂时升高,说明心肌一过性缺血引起血浆NT-proBNP水平一过性升高,比LVEF变化更灵敏。
作者 李岩
出处 《中国老年保健医学》 2015年第1期46-47,共2页 Chinese Journal of Geriatric Care
  • 相关文献

参考文献3

  • 1Staub D,Jonas N,Zellweger MJ, et al. Use of N-terminal pro ]', B-type natriureic peptide to detect myocardial ischcmia[ J ]. Am J Mcd, 2005,118:1287.
  • 2周丽程,郑杨.脑钠素、N-末端脑钠素前体与心血管疾病[J].中国心血管病研究,2007,5(12):937-939. 被引量:11
  • 3Januzzi JL, van Kimmenade R, Lainchbury J,et al. NT-proBNP testing for diagnosis and short-term prognosis in acute dcstabi lizcd heart fail- ure:an international pooled analysis of 1256 paticnts:the International Collaborative of NT-proBNP Study [ J ]. EurHcartJ, 2006, 27: 330 - 337.

二级参考文献17

  • 1肖春晖,吴小庆,羊镇宇,李肖蓉,王如兴.B型利钠肽与孤立性心房颤动[J].中国循环杂志,2007,22(1):31-34. 被引量:12
  • 2[1]Weber M,Hamm C.Role of B-type natriuretic peptide and NT-proBNP in clinical routine.Heart,2006,92:843-849.
  • 3[2]Mueller C,Scloler A,loule-Kilian K,et al.Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.N Engl J Med,2004,350:647-54.
  • 4[3]Steg PG,Joubin L,Mecord Jet al.B-Type natriuretic peptide and echocardio graphic determination of ejection fractioninthe diagnosis of congestive heart failure in patients with acute dyspnea.CHEST,2005,128:21-29.
  • 5[4]Januzzi JL Jr,Camargo CA,Anwaruddin S,et al.The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.Am J Cardiol,2005,95:948-954.
  • 6[5]Odar-Cederlof I,Bjellerup P,Williams A,et al.Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP),a biomarker of left ventricular dysfunction.Hemodial Int,2006,10:394-398.
  • 7[6]Knebel F,Schimke l,Plief K,et al.NT-ProBNP in acute heart failure:correlation with invasively measured hemodynamic parameters during recompensation.J Card Fail,2005,11(Suppl 5):S38-S41.
  • 8[8]Heart Protection Study Collaborative Group,Emberson JR.N-terminal Pro-B-type natriu retic peptide,vascular disease risk,and cholesterol reduction among 20 536 patients in the MRC/BHF heart protection study.J Am Coll Car diol,2007,49:311-319.
  • 9[9]Brenden CK,Hollander JE,Guss D,et al.Gray zone BNP levels in heart failure patients in the emergen cy department:results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study.Am Heart J,2006,151:1006-1011.
  • 10[10]Weber M,Dill T,Amold R,et al.N-terminal B-Type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris.Am Heart J,2004,148:612-620.

共引文献10

同被引文献19

  • 1Magalhaes MA,Minha S,Chen F,et al.Response to letter regarding article,"Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations"[J].Circulation Cardiovascular Interventions,2015,8(4):210-214.
  • 2Lee K,Yoo SY,Suh J,et al.Efficacy of cilostazol on inhibition of platelet aggregation,inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention:The ACCEL-LOADING-ACS(ACCELerated inhibition of platelet aggregation,inflammation and myonecrosis by adjunctive cilostazol loading in patients with acute coronary syndrome)study[J].International Journal of Cardiology,2015,190(2):370-375.
  • 3Kluz K,Parenica J,Kubkova L,et al.Unstable angina pectoris prior to ST elevation myocardial infarction in patients treated with primary percutaneous coronary intervention has no influence on prognosis[J].Biomedical Papers of the Medical Faculty of the University Palacky,Olomouc,Czechoslovakia,2015,159(2):251-258.
  • 4Kizilirmak F,Gunes HM,Demir GG,et al.Impact of intracoronary adenosine on myonecrosis in patients with unstable angina pectoris undergoing percutaneous coronary intervention[J].Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy,2015,29(6):519-526.
  • 5Giustino G,Baber U,Stefanini GG,et al.Impact of clinical presentation(stable angina pectoris vs unstable angina pectoris or Non-ST-elevation myocardial infarction vs ST-elevation myocardial infarction)on long-term outcomes in women undergoing percutaneous coronary intervention with drug-eluting stents[J].The American Journal of Cardiology,2015,116(6):845-852.
  • 6Zhang XL,Chi YH,Wang le F,et al.Systemic inflammation in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention[J].Respirology,2014,19(5):723-729.
  • 7Loh JP,Pendyala LK,et al.Comparison of outcomes after percutaneous coronary intervention among different coronary subsets(stable and unstable angina pectoris and ST-segment and non-ST-segment myocardial infarction)[J].The American Journal of Cardiology,2014,113(11):1794-1801.
  • 8Liu HL,Yang Y,Yang SL,et al.Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients:a randomized clinical study[J].Clinical therapeutics,2013,35(3):261-272.
  • 9Li Q,Deng SB,Xia S,et al.Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention:a clinical study[J].Medicina Clinica,2013,140(12):532-536.
  • 10Jeong YH,Tantry US,Min JH,et al.Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention[J].International Journal of Cardiology,2013,168(1):427-435.

引证文献1

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部